Medrysone

Summary

Medrysone (CHEMBL1201173) is an approved small molecule (ATC S01BA08); indicated across 1 condition including eye disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: S01BA08
• Indications: 1 condition
• Chemistry: 344.5 Da · C22H32O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201173
Name	Medrysone
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	247839
ATC	S01BA08
Molecular formula	C22H32O3
Molecular weight	344.5
InChIKey	GZENKSODFLBBHQ-ILSZZQPISA-N

SMILES: C[C@H]1C[C@H]2[C@@H]3CC[C@@H]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)CC4)C)O)C)C(=O)C

IUPAC name: (6S,8S,9S,10R,11S,13S,14S,17S)-17-acetyl-11-hydroxy-6,10,13-trimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one

Also known as: Hydroxymesterone, Medrisona, Medrysone, NSC-63278, U-8471, SID11533031, MEDRYSONE, SID56423131, SID144204077, SID170465194, C0165061, medrysone

Patent coverage: 3,769 distinct patent families (15,233 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Survival motor neuron protein, Glucocorticoid receptor, Progesterone receptor, Androgen receptor, Cruzipain.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 5 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PGR	8.57	AC50	2.7	nM	CHEMBL_ACT_25223578
NR3C1	8.3	AC50	5	nM	CHEMBL_ACT_25176474
P15207	6.59	AC50	257	nM	CHEMBL_ACT_25187817
SMN1	5.85	Potency	1412	nM	CHEMBL_ACT_3866826

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
eye disorder	4	MONDO:0005328	EFO:0005752

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).